Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of IV nafithromycin in healthy adults
NCT02770404Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Apr 2016
- Primary completion
- Oct 2016
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in community-acquired bacterial pneumonia (CAP) comparing Nafithromycin with Placebo (2 arms). Primary endpoints: Area under the plasma concentration-time curve at 72 hours, Maximum observed plasma concentration at 72 hours and 1 more. Started Apr 2016; status: completed.
02
Drugs
nafithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02770404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770404.